Clinical Trial Update: Role of ALiskiren, a Direct Renin Inhibitor, in Preventing Atrial Fibrillation in Patients With a Pacemaker; RALF. [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating whether aliskiren can prevent atrial fibrillation in patients with a pacemaker.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Aliskiren (Aliskiren)

Snippet

Sponsor: Mika Lehto | Conditions: Atrial Fibrillation | Phase 3 | Status: UNKNOWN